Pancreatic enzyme products: Digesting the changes;Productos de Enzimas Pancreáticas; Digiriendo los Cambios

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages 658-666

  Giuliano, Christopher A ^a   Dehoorne Smith, Michelle L ^b   Kale Pradhan, Pramodini B ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Creon; Exocrine insufficiency; Pancreatic enzyme products; Pancreaze; Zenpep

Indexed keywords

AMYLASE; KREON; PANCREAS ENZYME; PANCREATIC ENZYME PRODUCT; PANCREATIN; PANCREAZE; PANCRELIPASE; PLACEBO; PROTEINASE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ZENPEP;

ABDOMINAL PAIN; ARTICLE; CHRONIC PANCREATITIS; COLON DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; CYSTIC FIBROSIS; DECREASED APPETITE; DEFECATION; DIAPER DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULARY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; FECES; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; NAUSEA; PANCREAS EXOCRINE INSUFFICIENCY; PANCREAS RESECTION; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINORRHEA; SATIETY; SIDE EFFECT; STEATORRHEA; TREATMENT FAILURE; URTICARIA; VOMITING; WEIGHT REDUCTION;

EXOCRINE PANCREATIC INSUFFICIENCY; GASTROINTESTINAL AGENTS; HUMANS; PANCREAS; PANCRELIPASE;

EID: 79957592269     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P770     Document Type: Article

References (47)

1. Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol 2006;41:35-49.DOI 10.1002/ppul.20286
2. Konstan MW, Butler SM, Wohl ME, et al. Growth and nutritional indexes in early life redict pulmonary function in cystic fibrosis. J Pediatr 2003;142:624-30. DOI S0022-3476(03)00059-310.1067/mpd.2003.152
3. Dutta SK, Bustin MP, Russell RM, Costa BS. Deficiency of fat-soluble vitamins in treated patients with pancreatic insufficiency. Ann Intern Med 1982;97:549-552.
4. Haaber AB, Rosenfalck AM, Hansen B, Hilsted J, Larsen S. Bone mineral metabolism, bone mineral density, and body composition in patients with chronic pancreatitis and pancreatic exocrine insufficiency. Int J Pancreatol 2000;27:21-27.DOI 10.1385/IJGC:27:1:21
5. Krishnamurty DM, Rabiee A, Jagannath SB, Andersen DK. Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis. Ther Clin Risk Manag 2009;5:507-520.
6. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. JAMA 1990;263:2459-2461.
7. Food and Drug Administration. Updated questions and answers for healthcare professionals and the public: use an approved pancreatic enzyme product (PEP). http://www.fda.gov/Drugs/DrugSafety/Postmarket-DrugSafetyInformationforP atientsandProviders/ucm204745.htm (accessed 2010 Nov 3).
8. Product information. Creon (pancrelipase). North Chicago, IL: Abbot Products, December 2010.
9. Product information. Zenpep (pancrelipase). Milan, Italy: Eurand, December 2009.
10. Product information. Pancreaze (pancrelipase). Titusville, NJ: Ortho-Mc-Neil-Janssen Pharmaceuticals, Inc., December 2010.
11. Pankaj P. Treatment of disorders of bowel motility and water flux; antiemetics; agents used in biliary and pancreatic disease. In: Brunton LL, Lazo J, Parker KL, ed. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York, NY. McGraw-Hill, Inc., 2006:1005-1006.
12. Keller J, Aghdassi AA, Lerch MM, Mayerle JV, Layer P. Tests of pancreatic exocrine function-clinical significance in pancreatic and non-pancreatic disorders. Best Pract Res Clin Gastroenterol 2009;23:425-439.DOI S1521-6918(09)00038-910.1016/j.bpg.2009.02.013
13. Chowdhury RS, Forsmark CE. Pancreatic function testing. Aliment Pharmacol Ther 2003;17:733-750.
14. Malabsorption. 5-Minute pediatric consult. Lippincott Williams and Wilkins. Lexi-comp (accessed 2010 Nov 3).
15. Borowitz D, Konstan M, O'Rourke A, Cohen M, Hendeles L, Murray FT. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther 2007;12:47-52.
16. Graff GR, McNamara J, Royall J, Caras S, Forssmann K. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, singletreatment-arm study. Clin Drug Invest 2010;30:351-364. DOI 110.2165/11533390-000000000-00000
17. Graff GR, Maguiness K, McNamara J, et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, twoperiod crossover, superiority study. Clin Ther 2010;32:89-103. DOI S0149-2918(10)00013 510.1016/j.clinthera.2010. 01.012
18. Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros 2009;8:370-377. DOI S1569-1993(09)00122-2 10.1016/j.jcf.2009.08.008
19. Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gastroenterol 2010;105:2276-86. DOI ajg2010201 10.1038/ajg.2010.201
20. Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros 2009;8:405-417.DOI S1569-1993(09)00096-4 10.1016/j.jcf.2009.07.006
21. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Vilarino-Insua M. Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts. Gut 2006;55:1056-1057.DOI 55/7/1056-a10.1136/gut.2006.094912
22. Vecht J, Symersky T, Lamers CB, Masclee AA. Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency. J Clin Gastroenterol 2006;40:721-725.DOI 00004836-200609000-00012
23. DiMagno EP. Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency. Best Pract Res Clin Gastroenterol 2001;15:477-486.DOI 10.1053/bega.2001.0195S1521691801901957
24. Vu MK, Vecht J, Eddes EH, Biemond I, Lamers CB, Masclee AA. Antroduodenal motility in chronic pancreatitis: are abnormalities related to exocrine insufficiency? Am J Physiol Gastrointest Liver Physiol 2000; 278:G458-G466.
25. Layer P, Brambs HJ, Ell C, et al. [1995 gastroenterology update-II]. Med Klin (Munich) 1996;91(suppl 1):81-88.
26. Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol 1986;251:G475-G480.
27. Layer P, Keller J. Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. J Clin Gastroenterol 1999;28:3-10.
28. Greenberger NJ. Enzymatic therapy in patients with chronic pancreatitis. Gastroenterol Clin North Am 1999;28:687-693.
29. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr 1995;127:681-684. DOI S002234769500535X
30. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35: 246-259.
31. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008;108:832-889.DOI S0002-8223(08)00179-X10.1016/j.jada.2008.02.020
32. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic- enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336(18):1283-1289. DOI 10.1056/NEJM199705013361803
33. Smyth RL, Ashby D, O'Hea U, et al. Fibrosing colonopathy in cystic fi- brosis: results of a case-control study. Lancet 1995;346:1247-1251. DOI S0140-6736(95)91860- 4
34. McKesson Pharmaceutical. Wholesaler pricing database. www.mckesson. com/en_us/McKesson.com/our%2BBusinesses/McKesson%2BPharmaceutical/Produc ts%2Band%2BServices.html (accessed 2011 Apr 27).
35. Berardi RR, Montgomery PA. Pancreatitis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 7th ed. New York, NY: McGraw-Hill, 2008: 659-673.
36. Pancrelipase. Drugdex. Greenfield Village, CO. Thomson Micromedex, expired 2010. (accessed 2011 Jan 20).
37. Food and Drug Administration. CFSAN-bad bug book-pH values of various foods. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/ucm204745.htm (accessed 2011 Jan 20).
38. National Institutes of Health. Creon after pancreatic surgery. www.clinicaltrials. gov/ct2/show/NCT00535756?term=Exocrine+pancreatic+ insufficiency&rank=34 (accessed 2010 Dec 1).
39. National Institutes of Health. A Study of EUR-1066 in subjects with chronic pancreatitis, exocrine pancreatic insufficiency and chronic abdominal pain. www.clinicaltrials.gov/ct2/show/NCT01159119?term=zenpep&rank=1(acces sed 2010 Dec 1).
40. National Institutes of Health. A study to evaluate the mode of administration in infants less than 12 months of EUR-1008. www.clinicaltrials.gov/ct2/show/NCT01100606?term=Exocrine+pancreatic+ins ufficiency&rank=17 (accessed 2011 Jan 20).
41. National Institutes of Health. Clinical non-inferiority of pancreatic enzymes (Norzyme-Bergamo) compared to Creon (Solvay Pharmaceutical) in patients with exocrine pancreatic insufficiency. www.clinicaltrials.gov/ct2/show/NCT01012908?term=Exocrine+pancreatic+ins ufficiency&rank=19 (accessed 2011 Jan 20).
42. National Institutes of Health. Intraduodenal aspiration study to assess the bioavailability of oral pancrecarb compared to placebo control. www. clinicaltrials.gov/ct2/show/NCT00744250?term=Exocrine+pancreatic+insuffi ciency&rank=15 (accessed 2011 Jan 20).
43. National Institutes of Health. An open-label study to evaluate the intraduodenal delivery of enzymes from administration of VIOKASE16 in exocrine pancreatic insufficiency (EPI). www.clinicaltrials.gov/ct2/show/NCT00559052?term=Exocrine+pancreatic+ins ufficiency&rank=11 (accessed 2011 Jan 20).
44. National Institutes of Health. Efficacy and safety of ULTRASE MT20 in improving the coefficient of fat absorption (CFA%) in children with cystic fibrosis (CF) and pancreatic insufficiency (PI). www.clinicaltrials. gov/ct2/show/NCT00513682?term=Exocrine+pancreatic+insufficiency&rank =10 (accessed 2011 Jan 20).
45. National Institutes of Health. ALTU-135 efficacy trial in patients with cystic fibrosis-related exocrine pancreatic insufficiency (DIGEST). www. clinicaltrials.gov/ct2/show/NCT00449878?term=Exocrine+pancreatic+insuffi ciency&rank=2 (accessed 2010 Dec 1).
46. National Institutes of Health. Efficacy of bucelipase alfa (BSSL) in patients with cystic fibrosis and pancreatic insufficiency. www.clinicaltrials. gov/ct2/show/NCT00743483?term=Exocrine+pancreatic+insufficiency&rank =7 (accessed 2010 Dec 1).
47. National Institutes of Health. Randomized double-blind placebo crossover study to evaluate safety/efficacy of two doses in CP patients with EPI. www.clinicaltrials.gov/ct2/show/NCT00788593?term=Exocrine+pancreatic+ins ufficiency&rank=13 (accessed 2010 Dec 1).